CalciMedica, Inc. Share-based Payment Arrangement, Expensed and Capitalized, Amount
CalciMedica, Inc. (CALC) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $540.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-08-11
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $540.00K, a 54.00% decline year-over-year.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $561.00K, a 2.19% increase year-over-year.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $622.00K, a 1.58% decline year-over-year.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $626.00K, a 19.85% decline year-over-year.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $2.97M, a 28.45% increase from fiscal 2024.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $2.31M, a 0.00% change from fiscal 2023.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $2.31M, a 28.00% increase from fiscal 2022.
- CalciMedica, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $1.81M.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $540.00K 10-Q · filed 2026-08-11 | $1.10M 10-Q · filed 2026-08-11 | $1.72M derived: sum of 3 quarters · filed 2026-08-11 | $2.35M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $561.00K 10-Q · filed 2026-05-12 | $1.18M derived: sum of 2 quarters · filed 2026-05-12 | $1.81M derived: sum of 3 quarters · filed 2026-05-12 | $2.98M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $622.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.25M derived: sum of 2 quarters · filed 2026-03-03 | $2.42M derived: sum of 3 quarters · filed 2026-08-11 | $2.97M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $626.00K 10-Q · filed 2025-11-12 | $1.80M derived: sum of 2 quarters · filed 2026-08-11 | $2.35M 10-Q · filed 2025-11-12 | $2.98M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.17M 10-Q · filed 2026-08-11 | $1.72M 10-Q · filed 2026-08-11 | $2.35M derived: sum of 3 quarters · filed 2026-08-11 | $3.14M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $549.00K 10-Q · filed 2026-05-12 | $1.18M derived: sum of 2 quarters · filed 2026-05-12 | $1.96M derived: sum of 3 quarters · filed 2026-05-12 | $2.45M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $632.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.41M derived: sum of 2 quarters · filed 2025-11-12 | $1.90M derived: sum of 3 quarters · filed 2025-11-12 | $2.31M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $781.00K 10-Q · filed 2025-11-12 | $1.27M derived: sum of 2 quarters · filed 2025-11-12 | $1.68M 10-Q · filed 2025-11-12 | -$8.08M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-06-30 | $486.00K 10-Q · filed 2025-08-12 | $900.00K 10-Q · filed 2025-08-12 | -$8.86M derived: sum of 3 quarters · filed 2026-03-03 | -$8.38M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2024-03-31 | $414.00K 10-Q · filed 2025-05-14 | -$9.34M derived: sum of 2 quarters · filed 2026-03-03 | -$8.86M derived: sum of 3 quarters · filed 2026-03-03 | -$8.40M derived: sum of 4 quarters · filed 2026-03-03 | |
| 2023-12-31 | -$9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$9.28M derived: sum of 2 quarters · filed 2026-03-03 | -$8.81M derived: sum of 3 quarters · filed 2026-03-03 | $2.31M 10-K · filed 2026-03-03 | $12.04M 10-K · filed 2024-03-28 |
| 2023-09-30 | $482.00K 10-Q · filed 2024-11-13 | $945.00K derived: sum of 2 quarters · filed 2024-11-13 | $12.07M 10-Q · filed 2024-11-13 | $12.46M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $463.00K 10-Q · filed 2024-08-12 | $11.59M 10-Q · filed 2024-08-12 | $11.98M derived: sum of 3 quarters · filed 2024-08-12 | $12.74M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $11.13M 10-Q · filed 2024-05-13 | $11.52M derived: sum of 2 quarters · filed 2024-05-13 | $12.28M derived: sum of 3 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $394.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.15M derived: sum of 2 quarters · filed 2024-03-28 | $1.81M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $757.00K 10-Q · filed 2023-11-09 | $1.41M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |